Concepedia

Author

Giuseppe Aprile

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Aprile Giuseppe, Aprile, G., Aprile, Giuseppe, Francesco Leone, G Aprile, G. APRILE, G. Aprile, G. Aprile Esq., G. aprile, Giuseppe Aprile

510

Publications

21.8K

Citations

56

H-Index

103

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoOspedale San BortoloAzienda Ospedaliera Universitaria PisanaIstituto Oncologico VenetoUniversity of Udine
GA

About

Giuseppe Aprile is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

34

67

15.1K

2

Health Sciences

9

10

694

3

Public Health

5

5

179

4

Biostatistics

3

3

152

5

Cell Biology

2

2

39

Giuseppe Aprile

×

141

Publications

18.5K

Citations

50

H-Index

YearCitations

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova,

The Lancet

2010

7.2K

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru,

The Lancet

2013

2.2K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung‐Jue Bang,

The Lancet

2023

609

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila,

JAMA Oncology

2018

397

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi,

Modern Pathology

2015

309

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini,

The Lancet Oncology

2020

309

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio,

The Lancet Oncology

2022

246

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso,

The Oncologist

2019

224

Page 1